Trial Profile
A retrospective study evaluating safety and efficacy of Nivolumab in patients with non-clear cell renal carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2017
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology